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Simple Summary: CD19+ Chimeric antigen receptor (CAR) T-cells are used against CD19+
hematologic malignancies, such as high-grade B-cell lymphoma and acute lymphoblastic leukemia.
Since this is a relatively new treatment approach, not all potential side effects are well described,
and the underlying pathobiology is often not well defined. Here, we summarize current data on the
incidence and the current management of CD19+ CAR T-cell complications. We discuss frequently
occurring toxicities and we highlight evidence for the occurrence of rarer side effects affecting different
organ systems. In addition, we highlight new findings that shed light on the pathophysiology of
CAR T-cell-related complications.
Abstract: Clinical trials demonstrated that CD19+ chimeric antigen receptor (CAR) T-cells can be
highly effective against a number of malignancies. However, the complete risk profile of CAR
T-cells could not be defined in the initial trials. Currently, there is emerging evidence derived from
post approval studies in CD19+ CAR T-cells demonstrating both short-term and medium-term
effects, which were unknown at the time of regulatory approval. Here, we review the incidence and
the current management of CD19+ CAR T-cell complications. We highlight frequently occurring
events, such as cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome,
cardiotoxicity, pulmonary toxicity, metabolic complications, secondary macrophage-activation
syndrome, and prolonged cytopenia. Furthermore, we present evidence supporting the hypothesis
that CAR T-cell-mediated toxicities can involve any other organ system and we discuss the potential
risk of long-term complications. Finally, we discuss recent pre-clinical and clinical data shedding new
light on the pathophysiology of CAR T-cell-related complications.
Keywords: chimeric antigen receptor; CAR T-cells; toxicity; complications; cytokine release syndrome;
CD19; lymphoma; leukemia
1. Background
CAR-T cells that target CD19 have become standard treatments of relapsed or refractory
hematological malignancies, such as B cell acute lymphoblastic leukemia (ALL) and relapsed or
refractory large B cell lymphoma (LBCL). In addition, numerous trials in further tumor entities are
under way, making it likely that in the near future, there will be a broader clinical use of CAR-T cells
with different antigen specificities.
The safety of CAR-T cells is of major concern, since this new class of antitumor therapy has
previously unknown side effects. The complete risk profile of CD19+ CAR T-cells could not be defined
in the relatively small initial trials leading to approval of CAR T-cell products. This led to the obligation
to document toxicities in any patient receiving commercial CAR T-cell products.
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Currently, there is emerging evidence demonstrating both short-term and medium-term effects,
which were in part unknown at the time of regulatory approval. However, a major hurdle towards
a better understanding is our incomplete knowledge on the underlying pathophysiology of some
of those complications. A challenge in the clinic is to predict the timelines of unwanted effects
because of the ability of CAR-T cells to persist and expand in vivo. Another challenge will be to
determine if the to-date detected side effects of CD19-targeting CAR T-cells may also apply to future
CAR T-cell therapies (CART) targeting other antigens. In addition, the toxicity profile of future
third- or fourth-generation CAR T-cell products has not been well defined. Second-generation CAR
constructs use one costimulatory signaling domain, whereas in third-generation CAR constructs,
two costimulatory domains are combined. In fourth-generation CAR constructs, further genes are
expressed, which may facilitate the activation of CAR T-cells. Therefore, there is the possibility that
third- or fourth-generation CAR T-cell products have additional toxicities or more severe forms of
similar toxicities. However, early data suggest that the toxicities may be lower as compared with the
current approved second-generation CAR-T products [1]. In this article, we discuss the available data
on toxicities of the commercially available second-generation CD19-targeting CAR T-cell products
and give an outlook on the expected toxicities of emerging CART (e.g., for multiple myeloma and
solid tumors).
2. Cytokine Release Syndrome
In response to contact with the target antigen, signaling through the CAR induces CAR T-cell
proliferation and cytokine production. This leads to a cascade of immune stimulation involving
the activation of macrophages. In a xenogeneic model of CRS using immunocompromised mice
injected with human CD19+ lymphoma cells as well as CD19+ CAR-T cells, a critical role of
macrophage-derived cytokines, such as IL-6, IL-1, and nitric oxide, has been demonstrated [2].
However, multiple inflammatory proteins are elevated in peripheral blood during CRS, including
C-reactive protein, ferritin, interferon-γ, interleukins (IL-1, IL-2Rα, IL-6, IL-8, IL-10, IL-15),
monocyte inflammatory proteins, monocyte chemoattractant proteins, and tumor necrosis
factor receptors.
An important step of the inflammatory cascade seems to be the activation of endothelial cells in
the microvasculature of different organs, resulting in capillary leakage. In patients with severe CRS,
angiopoietin-2 and serum von Willebrand factor were significantly increased. Moreover, both factors
were predictive of severe CRS when assessed prior to CAR-T cell therapy [3]. Other risk factors for
the development of CRS include high CAR T-cell and tumor cell numbers as well as low platelet
counts, comorbidities, and early onset of CRS [3–6]. Moreover, the costimulatory capabilities as well
as the antigen binding characteristics of the CAR construct are likely to determine the CRS risk [7].
The reported incidences of CRS are quite variable, with ranges between 30% and 100%, not only
depending on the presence of risk factors in the patient cohorts but also on different CRS grading
systems used in the literature [8–10]. The incidences of CRS reported in the literature are summarized
in Table 1. In accordance, the incidence of severe CRS (grades 3–4) has been reported to be in the
range from 10–30% [8,9]. Of note, more recent publications report lower incidences of severe CRS and
lower rates of intensive care unit treatments, especially in more recent CAR T cell products, which are
therefore applied in an outpatient setting [11]. Interestingly, in a recently reported phase 1/2 study,
a bicistronic CAR targeting CD19 and CD22 followed by an anti-PD1 showed no induction of ≥◦III
CRS [12].
In established CAR T cell products, this fact probably derives from improved management of
CRS, namely from an earlier start of effective (steroid) treatment, which was also shown in cohort 4 of
the ZUMA-1 study [13].
Recently, CD19-CAR-T cell products have been being tested in indolent B-NHL, such as
marginal zone lymphoma and follicular lymphoma, with remarkably high anti-lymphoma activity.
However, the frequency and severity of CRS was similar to that in LBCL [14].
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The typical onset of CRS is between day + 3 and +6 after CAR T-cell infusion, with clinical
manifestations ranging from mild pyrexia through severe cases of multi-organ dysfunction. Grading of
CRS is recommended using the ASTCT grading system, which is also supported by the EBMT
(Table 2) [9,15]. Pharmacologic management of CRS is adapted to the respective CRS grades [9,15].
Grade 1: Symptomatic treatment (e.g., anti-pyretics and fluids), considering broad-spectrum
antibiotics. In case of very high fiver or persistence for more than three days, consider Tocilizumab.
Grade 2: In addition, Tocilizumab 8 mg/kg (max. 800 mg), which can be repeated every 8 h for a
maximum of four administrations.
Grade 3: In addition, Dexamethasone 10–20 mg, which can be repeated every 6 h.
Grade 4: Methylprednisolone 1000 mg/day in exchange for Dexamethasone.
In refractory cases, other immunosuppressive agents, such as Siltuximab (anti IL-6) and Anakinra
(anti-IL-1 receptor) [16], as well as cytokine absorption methods, have been used successfully [17].
Grades 3 to 4 CRS are managed in intensive care units and standard approaches for cardiovascular and
pulmonary support are used.
Of note, a number of CART complications, which are depicted below, are associated or even
induced by higher grades of CRS. Table 3 summarizes prevention and therapy strategies for different
CD19+ CAR T-cell related complications.
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Table 1. Incidence of non-relapse mortality (NRM), cytokine-release syndrome (CRS), and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in
patients included in key clinical trials with commercially approved CAR T-cells (Tisa-cel and Ax-cel).
Reference Year Product Patients (n) NRM CRS ICAN
Phase I/IIa 2014 [6] Tisa-Cel 30 0%
All patients (100%) developed CRS
27% developed severe CRS requiring
hemodynamic support
43% of patients developed ICANS ranging
from delirium to global encephalopathy
Phase II ELIANA 2018 [18] Tisa-Cel 75 8%
77% of patients developed CRS of any grade
47% required ICU admission
25% required high-dose vasopressorsupport
40% of patients developed ICANS of
any grade
13% grade 3 ICANS
Zuma-1 [19] Axi-Cel 101 4% Grade 3 or worse CRS occurred in 11% of patients Grade 3 or worse neurological events in 32%of patients
Juliet [20] Tisa-Cel 93 0% Grade 3 or worse CRS occurred in 22% of patients Grade 3 or worse neurological events in 12%of patients
Real world (PMID: 32667831) Axi-Cel 122 6% Grade 3 or worse occurred in 16% of patients Grade 3 or worse neurological events in 35%
Table 2. Suggested CRS grading, modified ASTCT consensus statement supported by the EBMT recommendations [9,15].
CRS Parameter Grade 1 Grade 2 Grade 3 Grade 4
Temperature ≥ 38 ◦C Yes Yes/# Yes/# Yes/#
with
Hypotension No Not requiring a vasopressor Requiring one vasopressor Requiring more than one vasopressor
and/or +
Hypoxia No Requiring low-flow oxygen Requiring high-flow oxygen Requiring positive pressure (CPAP,BiPAP, mechanical ventilation)
# In patients receiving antipyretic or anti-inflammatory therapy (e.g. tocilizumab or steroids) fever is not required to grade CRS severity. + total CRS grade is determined by the highest
CRS parameter grading.
Cancers 2020, 12, 3445 5 of 17
Table 3. Recommendations on prevention as well as comments on the management of toxicities in patients receiving anti-CD19 CAR T-cells.
Complication Prevention Management/Comments
CRS Reduce tumor cell numbers prior to infusionLimit the number of infused CAR T-cells Antipyretics, Fluids, Toziclizumab, Steroids
ICANS
Reduce tumor cell numbers prior to infusion
Limit the number of infused CAR T-cells
Neurologic assessment and treatment of neurologic
diseases prior to CAR T-cell infusion
Steroids
Pulmonary complications Lung function tests before CAR T-cell infusion to assessthe risk Non-invasive ventilation
Cardiovascular toxicity Avoid cardiotoxic chemotherapy before CAR T-cellEcho to assess cardiac function
Reduce cardiovascular risk factors in long term
survivors
Secondary macrophage-activation syndrome Unknown how it can be prevented Hard to differentiate from severe CRSEtoposide, Emapalumab possible drugs
B-cell aplasia Cannot be prevented IgG Substitution
Prolonged cytopenia Preventive measures unknown Role of growth factor substitution unclear
Infections Protected environment during neutropenic phase
Anti-bacterial prophylaxis during neutropenic phase
PJP and herpes prophylaxis till approximately 6 months
post CAR T
Antifungal prophylaxis not standard
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3. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
The pathophysiology of ICANS is not well understood mainly because reliable animal models are
lacking and because patient material for research is often not available. However, in peripheral blood,
a multitude of inflammatory mediators are elevated, similar to the situation in CRS [21,22]. In ICANS,
the vascular pathobiology seems to play a central role, as endothelial activation and multifocal vascular
disorder have been found in the brain of patients with fatal neurotoxicity. In addition, biomarkers
for endothelial activation were predictive of neurotoxicity even before CAR T-cell administration [23].
Another potentially relevant recent finding is that mural cells, which surround the cerebral endothelium
and are critical for blood–brain barrier integrity, express CD19. This may help in explaining the
increased frequency of ICANS in patients receiving CD19-targeting immunotherapies [24]. It remains
to be determined if future CAR T-cell therapies targeting other antigens will have a lower incidence of
ICANS. Currently, the most important risk factor for the development of ICANS is the presence of severe
CRS. Other risk factors include a high tumor burden and preexisting neurologic disorders [8,21,22].
The reported incidences are variable in a range between 10% and 50% (summarized in Table 1).
Recent data showed a similar frequency of ICAN for other B-cell malignancies, such as indolent B-NHL
or mantle-cell lymphoma [14,25].
The time to onset of ICANS-related symptoms is more variable as compared to the onset
of CRS and was reported to be in a range of 1–34 days after CAR T-cell infusion [6,18,26,27].
Clinical presentation often starts with a deterioration in handwriting and later on, non-specific
symptoms, such as disturbances of attention, agitation, confusion, tremors, headaches, or seizures,
may occur. The mental status can be disturbed, ranging from minor changes to severe disturbances
(e.g., coma). Regularly, ICANS is reversible; however, infrequently, fatal cases due to hemorrhage or
cerebral edema may occur [28]. Grading of ICANS is performed according to the recommendations of
ACTCT and EBMT as shown in Table 4 [9,15]. The backbone of pharmacologic management of ICANS
is steroids according to the respective ICANS grades [9,15]. Grade 1 ICANS is typically not treated
with steroids. Dexamethasone (e.g., 10 mg every 6 h) is generally used in ICANS grade 2–3 whereas
high-dose methylprednisolone (e.g., 1000 mg) is often used in grade four ICANS. Steroids are tapered
over days to several weeks but there is a risk of recurrence of ICANS [29]. In case of refractory ICANS
despite high-dose steroids, there is no standard clinical approach.
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Table 4. Suggested ICANS grading, modified ASTCT consensus statement supported by the EBMT recommendations [9,15]. The total ICANS grade is determined by
the most severe neurotoxicity domain grading.
Neurotoxicity Domain. Grade 1 Grade 2 Grade 3 Grade 4
ICE Score + 9–7 6–3 2–0 0 unable to perform ICE
Depressed level
of consciousness Awakens spontaneously Awakens to voice Awakens only to tactile stimulus
Patient is unarousable or requires vigorous or
repetitive tactile stimuli to arouse. Stupor or coma.
Seizure None None Seizure not fulfilling criteria forgrade 4
Life-threatening prolonged seizure (>5 min); or
Repetitive clinical or electrical seizures without
return to baseline in between
Motor findings None None None Deep focal motor weakness such as hemiparesisor paraparesis
Elevated ICP/cerebral edema None None Focal/local edema onNeuroimaging #
Diffuse cerebral edema on neuroimaging;
decerebrate or decorticate posturing; or cranial
nerve VI palsy; or papilledema; or Cushing’s triad
+ ICE Score (max 10): (1) Orientation (4 points): time (year, month), place (city, hospital); (2) Naming (3 points): ability to name three standard objects of daily life; (3) Writing (1 point):
ability to write standard sentence; (4) Attention (1 point): ability to count backward; (5) Following commands (1 point): ability to follow simple commands. # Intracranial hemorrhage with
or without associated edema is not considered a neurotoxicity feature and is excluded from ICANS grading.
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4. Complications after CAR T-Cell Therapy Other than CRS or ICANS
Initial publications derived from the pivotal trials reported a limited number of patients
(<100 in most trials) with a limited observation period. However, in the last two to three years,
many more patients were treated with CAR T-cells, both with approved drugs and in clinical
trials. In the US-based CIBMTR database already >2000 patients and in the EBMT database
nearly 1000 patients with CAR T-cell therapy were included (current figures given at cibmtr.org
and ebmt.org). This explains why additional complications occurring at later time points or occurring
less frequently were reported, including neurologic events, cardiotoxicity, pulmonary toxicity, metabolic
complications, secondary macrophage-activation syndrome, prolonged cytopenia, certain infections,
immune-related events, and subsequent malignancies. Table 5 summarizes the published literature on
the incidence of CAR-T-related complications other than CRS and ICANS.
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Table 5. CAR-T-related complications (other than CRS and ICANS) reported in the literature. Blank spaces where left for parameters not reported in the respective
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5. Late Neurologic and Psychiatric Events
In a recent published report, about 10% of patients surviving CAR T-cell therapy longer than three
months had neurological events other than ICANS, including ischemic attacks, peripheral neuropathy,
and Alzheimer’s dementia [30]. The patho-mechanism behind this association is not known.
Furthermore, psychiatric events have been detected in 9% of patients undergoing CAR T-cells
in that study. However, 50% of those patients had a pre-existing psychiatric disorder [30]. It is not clear
whether such side effects are directly or indirectly associated with CAR T-cells, since pathophysiologic
mechanisms for these side effects are unclear and no sufficient control patients were included in
those analyses.
6. Cardiovascular Toxicities
Cardiovascular complications have been initially reported in children treated with CAR T-cells
for ALL. In the ELIANA trial, grade 3 toxicities of cardiovascular origin were hypotension,
fluid overload, and pulmonary edema in more than 5% of patients [6]. Additionally, cardiomyopathy
with left ventricular systolic dysfunction was detected in additional retrospective analyses.
However, such complications were reversible in most children weeks to months after CAR
T-cells [33–35].
In the adult patient population, at least two retrospective analyses were published for approved
CAR T-cell products. In one study, major cardiovascular events occurred in 17% of patients till one
month after CAR T-cell infusion [36]. In another retrospective monocentric study of 60 consecutive
adult patients with LBCL, who were treated either with axicabtagene ciloleucel or tisagenlecleucel,
48 cardiovascular adverse events were observed in 32 patients within one year after infusion [32].
Similar to the cardiovascular toxicities seen in the pediatric population, hypotension and fluid retention
were most common. Atrial fibrillation and hypertension were additional cardiovascular side effects in
adults. Of note, most cardiovascular events were detected in patients also developing CRS [32,36].
The prevailing patho-mechanism seems to be the exacerbation of pre-existing cardiovascular damage
caused by CRS-related stress.
7. Pulmonary Toxicity
Pulmonary toxicities are complications of special interest in the field of immunotherapies,
especially for checkpoint inhibitor therapies. In CAR T-cell therapy recipients, pulmonary toxicities
were manageable in most of the cases and no unsuspected lung toxicity occurred to date.
However, pulmonary complications are also more frequent in patients with higher grade CRS [32].
The most frequent pulmonary symptom was hypoxia, but also pleural effusion, pulmonary embolism,
allergic rhinitis, and pneumomediastinum were described [32]. To date, there is no comprehensive
analysis for lung toxicity in recipients of CAR T-cell therapy, especially long-term follow-up with
consecutive lung function tests, including transfer capacity of the lung, which are currently missing.
8. Metabolic Complications
In a recent study with 60 patients by Wudikarn and colleagues, metabolic toxicities after CART
were detected as a frequent complication [32]. Typical electrolyte abnormalities were hypokalemia,
hypophosphatemia, and hypocalcemia. Hyperglycemia and hypoglycemia were also frequent [19,20,32].
However, such complications are manageable, and persistence is not expected.
9. Secondary Macrophage-Activation Syndrome (sHLH/MAS)
A recent poll by the EBMT reported an estimated incidence of sHLH/MAS between 3% and
4% [37]. However, it is difficult to dissect secondary macrophage-activation syndrome after CART from
severe CRS because some of the diagnostic criteria are overlapping, leading to low practicability of the
conventional diagnostic criteria [37]. A reasonable solution that has been proposed recently is that the
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diagnosis of sHLH/MAS should be made in case of very high ferritin levels (e.g., >10,000 ng/mL) in
addition to the typical symptoms [38]. The management of sHLH/MAS after CAR T-cell therapy is
currently a matter of debate, but Tocilizumab and steroids are considered the therapeutic backbone.
Whether additional agents have positive effects is not yet clear. One opportunity is to administer
etoposide in reference to HLH/MAS management outside the setting of CAR T-cell therapy [39].
Another option is to use Emapalumab, an anti-interferon-gamma antibody, which is highly upregulated
during MAS/HLH [40].
10. B-Cell Aplasia
Single infusion with CD19-directed CAR T-cell products induces B-cell aplasia associated
with hypogammaglobulinemia, which is shown in numerous studies [6,41]. In most patients,
immunoglobulin replacement was used to prevent infectious complications. However, currently, it is
not clear whether replacement therapy adds to outcome/improved quality of life in CD19 CAR T-cell
patients [42]. Persistence of CD19-directed CAR T-cells will most probably maintain B-cell aplasia.
However, long-term studies will clarify whether CD19 CAR T-cell products will be active in the
recipient’s body for years. Whether B-cell aplasia or hypogammaglobulinemia will be of concern in
CART of other B-lineage target epitopes, such as BCMA, will be of interest.
11. Prolonged Cytopenia
Early, late, and prolonged hematotoxicity after CAR T-cells occur in different CAR constructs
and are the most common adverse events after lymphodepletion and CAR T-cell transfusion,
with neutropenia being the most frequent. Early cytopenia is frequent in >80% of patients, whereas late
cytopenia occurs in 30–40%. In a recent publication on late effects after CAR T-cell therapy, a persisting
(after day + 90) cytopenia rate of 16% was described [30]. Overall, between 8% and 18% of CAR
T-cell recipients were reported to have prolonged cytopenia. Lymphopenia is seen in 35% of patients
at 1 year after anti-CD19 CAR T-cell therapy. One study described that late hematologic toxicity is
most frequent in patients with CRS and in patients with a history of stem cell transplantation [43].
In patients with relapsed or refractory large B-cell lymphoma treated with axicabtagene ciloleucel
(ZUMA-1 and ZUMA-9 trials), 48% of patients had grade 3–4 cytopenia at day 30 (anemia 16%,
neutropenia 29%, and thrombocytopenia 42%). After two years, grade 3–4 cytopenia persisted in one
out of nine evaluable patients (11%) [31]. It is largely unknown which factors contribute to cytopenia,
e.g., insufficient or late hematopoietic recovery after CART. In one study, 83 patients receiving CD19
CART were evaluated for hematopoietic recovery. In this cohort, baseline cytopenia, higher grades of
CRS or ICANS, and higher peak of C-reactive protein or ferritin were associated with a lower likelihood
of complete count recovery [44]. Disease entities play a minor role, since cytopenia is observed in
different entities, such as myeloma, ALL, and lymphoma. The use of G-CSF might be beneficial in
patients without signs of cytokine release syndrome and prolonged cytopenia.
12. Infections and Vaccinations
It has been reported that in patients surviving day+90 after CAR T-cell therapy, late infections
occurred in approximately 60% of patients. Of those infections, 60% were bacterial infections, 31% were
viral infections (mostly respiratory viruses), and 9% were fungal infections [30]. In another study,
60 patients with LBCL were retrospectively analyzed for incidence, risk factors, and management of
infections [45]. In total, 101 infections were observed in this patient cohort, among them, 23 severe,
one life-threatening, and one lethal. The cumulative incidence of infections at one year was 63.3%.
Most infections were bacterial (57.2%), severe bacterial (29.6%), viral (44.7%), and fungal (4%).
The use of corticosteroids for management of CRS or ICANS was associated with an increased
risk of infections. It is recommended to use antimicrobial, antiviral, and antifungal prophylaxis in
patients after CART, not only in cytopenic patients. Most centers use Cotrimoxazol Trimethoprim and
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Aciclovir until approximately 6 months after CD19+ CAR T-cell infusion. However, antifungal therapy,
e.g., with Posaconazole, could also be considered.
Data on infection in the context of COVID-19 and CART are sparse. However, it was recently
reported that in a cohort of 77 patients with SARS/COV-2 infection receiving cellular therapy (autologous,
allogeneic, and CART), a favorable outcome was reported. Overall survival at one month after cellular
therapy was 78% [46]. This data suggest that COVID-19 infections in CAR T cell recipients might
be manageable. Nevertheless, robust data in a larger cohort is pending.
It is a matter of debate if, and when, patients after CD19 CAR T-cell therapy should be vaccinated
as these patients may have low vaccine responses. On the other hand, these patients often have
considerable risk for infections and the vaccination efficacy does not exclusively depend on CD19+
B-cell responses. In fact, patients after CD19+ CAR T-cell therapy may have persistence of plasma
cells and may be able to have adequate vaccine responses [47]. Therefore, the administration of
re-vaccination should be considered in all recipients of CAR T-cell therapy. We suggest performing
seasonal influenza A vaccinations, also for close relatives of the patient. Beginning at 6 months after
CAR T-cell infusion, a comprehensive re-vaccination boost can be started; however, live attenuated
vaccines should not be administered within the first year [48]. Recommended vaccinations are similar
to the re-vaccination schedule after allogeneic stem cell transplantation [49]. Of note, the assessment of
anti-infectious antibody levels (titers) in patients after substitution of immunoglobulins is misleading
and not recommended.
13. Immune-Related Events and GVHD
In a study on later effects after CAR T-cell therapy, an incidence of 8% of immune-related events
was reported, including alveolitis, pneumonitis, persistent skin rash, collagenous colitis, and persistent
flu-like syndrome [30]. Generally, it is not expected that autologous or allogeneic donor-derived
CAR T cells induce or trigger GVHD or GVHD-like symptoms [50]. However, in another study,
out of 15 patients receiving CAR T-cells after previous allogeneic HCT, 3 patients (20%) developed
GVHD requiring systemic therapy [30]. This is an important side effect, which might be even more
frequent when third-party CAR T cell products are introduced, unless the endogenous T cell receptor
is genetically deleted or inactivated. Taken together, GVHD might be a side effect of special interest
and if suspected standard therapy is recommended [9].
14. Subsequent Malignancies
In a study on late effects after CD19 CAR T-cell therapy with a median duration of follow-up
of around 28 months, 21 out of 86 patients had ongoing CR. Six of those patients (29%) developed
subsequent malignant disease (2 MDS, 1 melanoma, 2 non-melanoma skin cancer, and 1 multiple
myeloma) [30]. However, a follow-up period of 2.5 years is most probably not sufficient to estimate the
frequency of secondary malignancies after CART, since the development of malignancies is typically
associated with latency [51]. Furthermore, it will be difficult to evaluate this risk independently of
cytostatic therapy before CART.
15. Potential Risk of other Long-Term Complications and Implications of the Available Evidence
for Clinical Care
Since CAR T-cell therapy is based on genetic manipulation of recipients’ lymphocytes, one has to be
aware of genotoxicity, such as lymphoma induction/tumor induction, itself [52], To date, this long-term
risk cannot be estimated and it is important to perform long-term surveillance. In the future routine
checkups for monitoring and prevention, unexpected or rare organ toxicities will be necessary. Data
on CAR T cell persistence will also be of major importance to estimate the risk of long-term organ
toxicities. Such recommendations will be based on mature outcome data, years after the approval
of CART.
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16. Outlook and Future Perspectives
A major future effort will be to reduce CAR T-cell treatment-related toxicities. There are
numerous disease- and patient-related variables that contribute to the risk of toxicities, such as
co-morbidities, age, tumor type, tumor cell burden, and conditioning therapy. However, modifications
in the CAR T-cell product characteristics offer the most promising perspective to decrease toxicities.
Specifically, the design of optimized CAR constructs may lead to the opportunity to reduce toxicities.
This review is limited by the fact that we mainly focused on two products (Tisa-cel and Axi-cel)
in which long-term data/post approval data was available. A variety of new CART are underway,
for LBL, such as Liso-cel, mantle cell lymphoma Brexucabtagen autoleucel, and Ide-cel, orva-cel, and
the JNJ-4528 for multiple myeloma. Furthermore, a recent report describes the generation of a CD19
41BB construct with a lower production of cytokines and slower proliferation kinetic. No significant
elevation in serum cytokine levels after CAR T cell infusion were detected and no CRS or neurotoxicity
occurred in the 11 patients treated with this construct [53]. Recently, data on allogeneic CD19 CAR-T
cell constructs with an eliminated endogenous T cell receptor were reported. Safety data on this third
party off the shelf CART was encouraging, since no GVHD occurred and ≥◦III CRS/ICAN rates were
rather low [54].
In addition, a better understanding of the pathophysiology of CAR T-cell-related complications will
be critical. Animal models that were developed recently could be the key to a better understanding [2,55].
The development of therapies aimed at the normalization of endothelial dysfunction, which is associated
to CAR T-cell-related complications, may be specifically promising [3,23,56].
A major concern regarding CART outside the CD19 setting is on-target off-tumor toxicities.
The difficulty is that there is a lack of suitable tumor neo-antigens and the majority antigens that are
under investigation in CAR T-cells trials have a considerable expression in normal tissues. As a result,
the use of CAR-T cells for the treatment of solid tumors may have an increased risk of severe toxicities
as compared with CD19-specific CAR T-cells [57,58].
17. Conclusions
CD19+ CAR T-cells are promising new treatment options for patients with certain types of
leukemia and lymphoma. However, there are considerable toxicities, such as cytokine release
syndrome, immune effector cell-associated neurotoxicity syndrome, cardiotoxicity, pulmonary toxicity,
metabolic complications, secondary macrophage-activation syndrome, and prolonged cytopenia.
Optimization of the management of these unwanted short-term and medium-term effects could further
improve clinical outcome.
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